Literature DB >> 23585605

Clinically important interaction between metoprolol and propafenone.

Jana Duricova1, Ilona Perinova, Nikola Jurckova, Ivana Kacirova, Milan Grundmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23585605      PMCID： PMC3625083     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  15 in total

1.  Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.

Authors:  B A Hamelin; A Bouayad; J Méthot; J Jobin; P Desgagnés; P Poirier; J Allaire; J Dumesnil; J Turgeon
Journal:  Clin Pharmacol Ther       Date:  2000-05       Impact factor: 6.875

2.  The relationship between metoprolol plasma concentration and beta 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations.

Authors:  B Abrahamsson; P Lücker; B Olofsson; C G Regårdh; A Sandberg; I Wieselgren; R Bergstrand
Journal:  J Clin Pharmacol       Date:  1990-02       Impact factor: 3.126

3.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.

Authors:  S V Otton; T Inaba; W Kalow
Journal:  Life Sci       Date:  1984-01-02       Impact factor: 5.037

4.  Interaction of metoprolol and fluoxetine.

Authors:  T Walley; M Pirmohamed; C Proudlove; D Maxwell
Journal:  Lancet       Date:  1993-04-10       Impact factor: 79.321

Review 5.  Clinical pharmacokinetics of metoprolol.

Authors:  C G Regårdh; G Johnsson
Journal:  Clin Pharmacokinet       Date:  1980 Nov-Dec       Impact factor: 6.447

6.  Drug interaction between propafenone and metoprolol.

Authors:  F Wagner; D Kalusche; D Trenk; E Jähnchen; H Roskamm
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

7.  Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.

Authors:  R E Jonkers; R P Koopmans; E J Portier; C J van Boxtel
Journal:  J Pharmacol Exp Ther       Date:  1991-03       Impact factor: 4.030

8.  Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism.

Authors:  H K Kroemer; C Fischer; C O Meese; M Eichelbaum
Journal:  Mol Pharmacol       Date:  1991-07       Impact factor: 4.436

9.  The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone.

Authors:  J T Lee; H K Kroemer; D J Silberstein; C Funck-Brentano; M D Lineberry; A J Wood; D M Roden; R L Woosley
Journal:  N Engl J Med       Date:  1990-06-21       Impact factor: 91.245

Review 10.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.

Authors:  Ulrich M Zanger; Sebastian Raimundo; Michel Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-15       Impact factor: 3.000
View more
  2 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 2.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.